Loading
LIV-2008/2008b is an experimental humanized monoclonal antibody from Chiome Bioscience, in preclinical development for triple-negative breast cancer, lung cancer and colorectal cancer.
LIV-2008/2008b (LIV-2008, LIV-2008b) is a humanized monoclonal antibody from Chiome Bioscience. A humanized anti-TROP-2 (TROP2) antibody generated by hybridoma technology. Its furthest stage is preclinical development, for triple-negative breast cancer, lung cancer and colorectal cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed as 'Licensing opportunity'. It has not been shown to work in people.
A humanized anti-TROP-2 (TROP2) antibody generated by hybridoma technology. Connects to TROP2.
1.LIV-2008/2008b binds TROP2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LIV-2008/2008b" OR ABSTRACT:"LIV-2008/2008b" OR TITLE:"LIV-2008" OR ABSTRACT:"LIV-2008" OR TITLE:"2008b" OR ABSTRACT:"2008b" OR TITLE:"LIV-2008b" OR ABSTRACT:"LIV-2008b") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LIV-2008/2008b, not a curated reading list.
Shares Chiome Bioscience and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares TROP2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/